Product Description
An inhibitor of the bromodomain and extra-terminal (BET) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor INCB054329 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular growth. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bet-inhibitor-incb054329)
Mechanisms of Action: BET Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Incyte
Company Location: Eastern America
Company CEO: Hervé Hoppenot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Prostate Cancer|B-Cell Leukemia|Pancreatic Cancer|NUT Carcinoma|Non-Small-Cell Lung Cancer|Myelofibrosis|Breast Cancer|Colorectal Cancer|Large Cell Carcinoma|Diffuse Large B-Cell Lymphoma|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Burkitt Lymphoma|Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03896815 |
I-54329-17-01 | N/A |
No longer available |
Renal Cell Carcinoma |
None |
2019-04-02 |
Treatments |
|
NCT02431260 |
INCB 54329-101 | P2 |
Terminated |
Myelodysplastic Syndrome|Prostate Cancer|Multiple Myeloma|Pancreatic Cancer|Large Cell Carcinoma|Colorectal Cancer|Breast Cancer|Myelofibrosis|Burkitt Lymphoma|B-Cell Leukemia|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|NUT Carcinoma|Adenocarcinoma|Diffuse Large B-Cell Lymphoma |
2018-01-31 |
23% |
2019-06-15 |
Start Date|Treatments|Trial Status |